Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QazCoVac-P COVID-19 Subunit Vaccine in Healthy Adults
NCT04930003Phase 2Completed
- Sponsor
- Research Institute for Biological Safety Problems
- Start
- Jun 2021
- Primary completion
- Dec 2021
- Modality
- Recombinant Proteins and Enzymes, Split/Subunit Vaccines, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of QazCoVac-P in coronavirus disease 2019 (COVID-19), sponsored by Research Institute for Biological Safety Problems. Started Jun 2021; status: completed.
02
Drugs
QazCoVac-P
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04930003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04930003.